EICHOR
● Completed
Addressing Involuntary Movements in Tardive Dyskinesia
Condition: Tardive Dyskinesia · Sponsor: Auspex Pharmaceuticals, Inc.
About this study
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (106)
| Teva Investigational Site 145 | Tuscaloosa, Alabama, United States | — |
| Teva Investigational Site 107 | Anaheim, California, United States | — |
| Teva Investigational Site 108 | Anaheim, California, United States | — |
| Teva Investigational Site 123 | Glendale, California, United States | — |
| Teva Investigational Site 177 | Imperial, California, United States | — |
| Teva Investigational Site 160 | Irvine, California, United States | — |
| Teva Investigational Site 106 | Irvine, California, United States | — |
| Teva Investigational Site 176 | Loma Linda, California, United States | — |
| Teva Investigational Site 121 | Los Angeles, California, United States | — |
| Teva Investigational Site 147 | Los Angeles, California, United States | — |
| Teva Investigational Site 174 | Norwalk, California, United States | — |
| Teva Investigational Site 170 | Oceanside, California, United States | — |
+ 94 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.